CDK4 and breast carcinoma: In breast cancer models, cells activate autophagy in response to Palbociclib, and a blockade of autophagy significantly improved the efficacy of CDK4/6 inhibition in in vitro and in vivo breast cancer models with an intact G1/S transition [30].